These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 30977837)

  • 1. Letter to the Editor: "Alemtuzumab-Induced Thyroid Dysfunction Exhibits Distinctive Clinical and Immunological Features".
    Garrahy A; Murphy NP; Byrne MM
    J Clin Endocrinol Metab; 2019 Sep; 104(9):3624-3625. PubMed ID: 30977837
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to Letter to the Editor: "Alemtuzumab-Induced Thyroid Dysfunction Exhibits Distinctive Clinical and Immunological Features".
    Thakar R; Gajewska-Knapik K; Ogilvy-Stuart AL; Chatterjee K; Moran C
    J Clin Endocrinol Metab; 2019 Sep; 104(9):3626-3627. PubMed ID: 30977836
    [No Abstract]   [Full Text] [Related]  

  • 3. Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis.
    Daniels GH; Vladic A; Brinar V; Zavalishin I; Valente W; Oyuela P; Palmer J; Margolin DH; Hollenstein J
    J Clin Endocrinol Metab; 2014 Jan; 99(1):80-9. PubMed ID: 24170099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management.
    Decallonne B; Bartholomé E; Delvaux V; D'haeseleer M; El Sankari S; Seeldrayers P; Van Wijmeersch B; Daumerie C
    Acta Neurol Belg; 2018 Jun; 118(2):153-159. PubMed ID: 29372482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alemtuzumab Induced Thyroid Disease in Multiple Sclerosis: A Review and Approach to Management.
    Mahzari M; Arnaout A; Freedman MS
    Can J Neurol Sci; 2015 Sep; 42(5):284-91. PubMed ID: 25990097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ocular Findings in Alemtuzumab (Campath-1H)-induced Thyroid Eye Disease.
    Trinh T; Haridas AS; Sullivan TJ
    Ophthalmic Plast Reconstr Surg; 2016; 32(6):e128-e129. PubMed ID: 25794019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Graves' disease after treatment with alemtuzumab for multiple sclerosis.
    Tsourdi E; Gruber M; Rauner M; Blankenburg J; Ziemssen T; Hofbauer LC
    Hormones (Athens); 2015; 14(1):148-53. PubMed ID: 25402383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re: letter to the editor on "Alemtuzumab induction in renal transplantation: a meta-analysis and systemic review".
    Zhang X; Wang L
    Transpl Immunol; 2013 Mar; 28(2-3):72. PubMed ID: 23352934
    [No Abstract]   [Full Text] [Related]  

  • 9. Autoimmune thyroid disease following treatment with alemtuzumab for multiple sclerosis.
    Alamo A; Condorelli RA; La Vignera S; Calogero AE
    Int J Immunopathol Pharmacol; 2019; 33():2058738419843690. PubMed ID: 30968726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological effects and safe administration of alemtuzumab (MabCampath) in advanced B-cLL.
    Kennedy B; Hillmen P
    Med Oncol; 2002; 19 Suppl():S49-55. PubMed ID: 12180492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients.
    Hill P; Cross NB; Barnett AN; Palmer SC; Webster AC
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004759. PubMed ID: 28073178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy.
    Esfahani K; Buhlaiga N; Thébault P; Lapointe R; Johnson NA; Miller WH
    N Engl J Med; 2019 Jun; 380(24):2375-2376. PubMed ID: 31189042
    [No Abstract]   [Full Text] [Related]  

  • 13. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.
    von Kutzleben S; Pryce G; Giovannoni G; Baker D
    Immunology; 2017 Apr; 150(4):444-455. PubMed ID: 27925187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Alemtuzumab, a monoclonal antibody against CD52: hopes and fears].
    Mori M
    Brain Nerve; 2014 Oct; 66(10):1179-89. PubMed ID: 25296872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond.
    Ruck T; Bittner S; Wiendl H; Meuth SG
    Int J Mol Sci; 2015 Jul; 16(7):16414-39. PubMed ID: 26204829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of alemtuzumab therapy for the treatment of T-cell lymphomas.
    Zinzani PL; Corradini P; Gallamini A; Grossi A; Lazzarino M; Marchetti M; Martelli M; Rossi G; Vitolo U
    Leuk Lymphoma; 2012 May; 53(5):789-95. PubMed ID: 21980956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging role of Alemtuzumab in renal and renal-pancreas transplantation.
    Sureshkumar KK; Hussain SM; Zimmer BW; Marcus RJ
    Expert Opin Biol Ther; 2008 Oct; 8(10):1605-25. PubMed ID: 18774927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weight-based dosing of alemtuzumab: an ounce of prevention?
    Augustine JJ
    Transpl Int; 2017 Nov; 30(11):1095-1097. PubMed ID: 28556989
    [No Abstract]   [Full Text] [Related]  

  • 19. ALAIN01--Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential.
    Ruck T; Afzali AM; Lukat KF; Eveslage M; Gross CC; Pfeuffer S; Bittner S; Klotz L; Melzer N; Wiendl H; Meuth SG
    BMC Neurol; 2016 Mar; 16():34. PubMed ID: 26966029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alemtuzumab (Millennium/ILEX).
    Dumont FJ
    Curr Opin Investig Drugs; 2001 Jan; 2(1):139-60. PubMed ID: 11527007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.